Lysosomal ion channels: TRPML1, TRPML2, TRPML3, TMEM175, and TPC2.

Whether you're a small biotech managing tight budgets or a large pharma striving for efficiency, Metrion is here to help you do more with less.

We mark Rare Disease Day by highlighting a selection of the most detrimental ion channel mutations which can result in a plethora of rare diseases, often involving complex neurological, cardiac, and muscular manifestations.

"The data is always correct and is in a format that imports directly into our systems, making it so quick and easy for our team to review the data across individual projects."

Insight into the history of how automated patch clamp has contributed to enhancing decision making, minimising risk and lowering R&D costs

The future of drug discovery holds immense promise, and Metrion is well-positioned to make meaningful contributions to advancing human health. I look forward to embarking on this exciting journey with all of you.

As we celebrate this significant milestone, we take pride in the contributions of our entire team, whose expertise and dedication have been instrumental in shaping who we are today. We’re equally grateful to our customers and collaborators, whose trust and partnership have been pivotal to our success.

Recording and Q&A from webinar 'Recent Progress Towards a Potential Treatment for KCNC-1 Related Disorders'

With enthusiastic engagement from staff, we’ve cultivated a robust H&S culture, ensuring we continuously prioritize the health, safety, and well-being of everyone at Metrion.

IQ Consortium’s In Vitro Secondary Pharmacology Profiling Working Group article ‘The state of the art in secondary pharmacology and its impact on the safety of new medicines’ recognised as the ‘Most Impactful Safety Pharmacology Publication of the Year’.